• Department of Endocrinology, the Second People's Hospital of Hefei, Hefei, Anhui 230011, P. R. China;
ZHANGXin-xiu, Email: zhangxinxiu6@126.com
Export PDF Favorites Scan Get Citation

Objective To analyze and summarize the clinical characteristics, risk factors, pathogenic bacteria type, and drug tolerance of diabetes complicated with hospital-acquired pulmonary infection, in order to reduce the incidence of hospital-acquired pulmonary infection in patients with diabetes. Methods The clinical data of diabetic patients with hospital-acquired pulmonary infection from 2011 to 2013 were taken for retrospective clinical analysis. Results A total of 78 diabetic patients had hospital-acquired pulmonary infection among all the 572 hospitalized patients with diabetes. Age, complications of diabetes, chronic underlying disease, duration of hospital stay, glycated hemoglobin and invasive procedures were all correlated with the incidence of hospital-acquired infection (P<0.05). Through sputum culture and throat culture, 59 strains of pathogens were found, and they were mainly multidrug-resistant Gram-negative bacteria, accounting for 71.2%. Conclusion The rate of acquired pulmonary infection in diabetic patients is particularly high, and the pathogens are mostly Gram-negative and multidrug-resistant. Glycemic control, rational use of antimicrobial drugs, shorter hospital stay, effective prevention and treatment of diabetes complications and chronic underlying diseases, and aseptic techniques can be effective in preventing acquired pulmonary infection for diabetic patients.

Citation: SONGJia-jia, ZHANGXin-xiu, LIUKe-mei. Clinical Analysis on Diabetes Patients Complicated with Hospital-acquired Lung Infection. West China Medical Journal, 2015, 30(3): 451-454. doi: 10.7507/1002-0179.20150129 Copy

  • Previous Article

    Preservation of the Facial Nerve during Acoustic Neuronoma Excision and Investigation of the Anatomical Location and Shape of Facial Nerve
  • Next Article

    Screening of Hepatitis B Virus Infection before Chemotherapy for Patients with Lymphoma